FibroGen Inc (NASDAQ:FGEN) CEO Thomas B. Neff sold 39,636 shares of FibroGen stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $44.97, for a total transaction of $1,782,430.92. Following the completion of the transaction, the chief executive officer now owns 2,425,974 shares in the company, valued at $109,096,050.78. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Shares of NASDAQ FGEN traded up $0.42 during trading on Friday, hitting $45.60. 303,056 shares of the company were exchanged, compared to its average volume of 757,640. The stock has a market cap of $3.88 billion, a P/E ratio of -44.27 and a beta of 1.85. FibroGen Inc has a 1 year low of $33.51 and a 1 year high of $67.85. The stock has a fifty day moving average price of $40.96. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.16 and a current ratio of 6.16.
FibroGen (NASDAQ:FGEN) last issued its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.15. The company had revenue of $23.90 million for the quarter, compared to analyst estimates of $20.44 million. FibroGen had a negative net margin of 44.14% and a negative return on equity of 17.71%. The business’s revenue was down 25.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.50) EPS. As a group, sell-side analysts forecast that FibroGen Inc will post -0.87 earnings per share for the current year.
FGEN has been the topic of several research analyst reports. Zacks Investment Research lowered shares of HEXO from a “hold” rating to a “sell” rating in a research report on Wednesday, May 15th. Goldman Sachs Group upgraded shares of Koninklijke KPN from a “neutral” rating to a “buy” rating in a research report on Wednesday, May 29th. TheStreet lowered shares of WESCO International from a “b-” rating to a “c+” rating in a research report on Friday, May 24th. ValuEngine lowered shares of Zumiez from a “hold” rating to a “sell” rating in a research report on Tuesday, July 2nd. Finally, William Blair restated a “hold” rating on shares of FibroGen in a research report on Tuesday, July 2nd. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. FibroGen presently has an average rating of “Buy” and a consensus price target of $61.57.
Several hedge funds and other institutional investors have recently modified their holdings of the business. Hillhouse Capital Advisors Ltd. acquired a new position in shares of FibroGen during the 4th quarter worth $92,712,000. FMR LLC raised its stake in shares of FibroGen by 8.7% during the 4th quarter. FMR LLC now owns 9,760,216 shares of the biopharmaceutical company’s stock worth $451,702,000 after buying an additional 778,980 shares during the last quarter. Norges Bank acquired a new position in shares of FibroGen during the 4th quarter worth $32,604,000. Fiera Capital Corp acquired a new position in shares of FibroGen during the 1st quarter worth $34,161,000. Finally, Janus Henderson Group PLC raised its stake in shares of FibroGen by 27.3% during the 1st quarter. Janus Henderson Group PLC now owns 2,208,759 shares of the biopharmaceutical company’s stock worth $120,046,000 after buying an additional 473,042 shares during the last quarter. Institutional investors own 66.27% of the company’s stock.
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
Further Reading: What is a Special Dividend?
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.